10x Genomics, Inc.
For the period ended Dec 31, 2025. Filed Feb 13, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 13, 2026
TXG$65.05+9.7%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Comprehensive Loss
(In thousands)
| December 31, | |||
|---|---|---|---|
| 2025 | 2024 | 2023 | |
| Net loss | $(43,544) | $(182,627) | $(255,099) |
| Other comprehensive income (loss), net of tax: | |||
| Unrealized gains (losses) on available-for-sale marketable securities | (6) | 206 | 2,210 |
| Realized loss on available-for-sale marketable securities reclassified into net loss | — | 3 | 1,718 |
| Foreign currency translation adjustment | 724 | (273) | (22) |
| Other comprehensive income (loss), net of tax | 718 | (64) | 3,906 |
| Comprehensive loss | $(42,826) | $(182,691) | $(251,193) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.